197 related articles for article (PubMed ID: 29715082)
1. Efficacy of Asparaginase
Sanghez V; Chen M; Li S; Chou TF; Iacovino M; Lin HJ; Lasky JL; Panosyan EH
Anticancer Res; 2018 May; 38(5):2627-2634. PubMed ID: 29715082
[TBL] [Abstract][Full Text] [Related]
2. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Panosyan EH; Wang Y; Xia P; Lee WN; Pak Y; Laks DR; Lin HJ; Moore TB; Cloughesy TF; Kornblum HI; Lasky JL
Mol Cancer Res; 2014 May; 12(5):694-702. PubMed ID: 24505127
[TBL] [Abstract][Full Text] [Related]
3. Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.
Emadi A; Law JY; Strovel ET; Lapidus RG; Jeng LJB; Lee M; Blitzer MG; Carter-Cooper BA; Sewell D; Van Der Merwe I; Philip S; Imran M; Yu SL; Li H; Amrein PC; Duong VH; Sausville EA; Baer MR; Fathi AT; Singh Z; Bentzen SM
Cancer Chemother Pharmacol; 2018 Jan; 81(1):217-222. PubMed ID: 29119293
[TBL] [Abstract][Full Text] [Related]
4. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
5. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
[TBL] [Abstract][Full Text] [Related]
6. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines.
Ramachandran C; Nair SM; Escalon E; Melnick SJ
J Complement Integr Med; 2012 Aug; 9():Article 20. PubMed ID: 22944718
[TBL] [Abstract][Full Text] [Related]
8. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
9. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Garros-Regulez L; Aldaz P; Arrizabalaga O; Moncho-Amor V; Carrasco-Garcia E; Manterola L; Moreno-Cugnon L; Barrena C; Villanua J; Ruiz I; Pollard S; Lovell-Badge R; Sampron N; Garcia I; Matheu A
Expert Opin Ther Targets; 2016; 20(4):393-405. PubMed ID: 26878385
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Gupta V; Su YS; Wang W; Kardosh A; Liebes LF; Hofman FM; Schönthal AH; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E20. PubMed ID: 16709026
[TBL] [Abstract][Full Text] [Related]
11. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
12. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Volpin F; Casaos J; Sesen J; Mangraviti A; Choi J; Gorelick N; Frikeche J; Lott T; Felder R; Scotland SJ; Eisinger-Mathason TSK; Brem H; Tyler B; Skuli N
Oncogene; 2017 May; 36(21):3037-3047. PubMed ID: 27941882
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
14. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
15. Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Proske J; Walter L; Bumes E; Hutterer M; Vollmann-Zwerenz A; Eyüpoglu IY; Savaskan NE; Seliger C; Hau P; Uhl M
Anticancer Res; 2016 Mar; 36(3):899-905. PubMed ID: 26976976
[TBL] [Abstract][Full Text] [Related]
16. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Saito R; Bringas JR; Panner A; Tamas M; Pieper RO; Berger MS; Bankiewicz KS
Cancer Res; 2004 Oct; 64(19):6858-62. PubMed ID: 15466173
[TBL] [Abstract][Full Text] [Related]
17. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
[TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Plowman J; Waud WR; Koutsoukos AD; Rubinstein LV; Moore TD; Grever MR
Cancer Res; 1994 Jul; 54(14):3793-9. PubMed ID: 8033099
[TBL] [Abstract][Full Text] [Related]
19. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
[TBL] [Abstract][Full Text] [Related]
20. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
